188 related articles for article (PubMed ID: 32741965)
21. Simple and rapid characterization of novel large germline deletions in SDHB, SDHC and SDHD-related paraganglioma.
Hoekstra AS; van den Ende B; Julià XP; van Breemen L; Scheurwater K; Tops CM; Malinoc A; Devilee P; Neumann HP; Bayley JP
Clin Genet; 2017 Apr; 91(4):536-544. PubMed ID: 27485256
[TBL] [Abstract][Full Text] [Related]
22. A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant.
Foley M; Sharma A; Garfield K; Maese L; Buchmann L; Boyle J; Kohlmann W; Jeter J; Greenberg S
Fam Cancer; 2023 Apr; 22(2):217-224. PubMed ID: 36223042
[TBL] [Abstract][Full Text] [Related]
23. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
24. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions.
Gabriel S; Blanchet EM; Sebag F; Chen CC; Fakhry N; Deveze A; Barlier A; Morange I; Pacak K; Taïeb D
Clin Endocrinol (Oxf); 2013 Aug; 79(2):170-7. PubMed ID: 23230826
[TBL] [Abstract][Full Text] [Related]
26. Genetic testing for pheochromocytoma and paraganglioma: SDHx carriers' experiences.
Martins RG; Carvalho IP
J Genet Couns; 2021 Jun; 30(3):872-884. PubMed ID: 33604970
[TBL] [Abstract][Full Text] [Related]
27. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
[TBL] [Abstract][Full Text] [Related]
29. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
[TBL] [Abstract][Full Text] [Related]
30. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
[TBL] [Abstract][Full Text] [Related]
31. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
Astuti D; Latif F; Dallol A; Dahia PL; Douglas F; George E; Sköldberg F; Husebye ES; Eng C; Maher ER
Am J Hum Genet; 2001 Jul; 69(1):49-54. PubMed ID: 11404820
[TBL] [Abstract][Full Text] [Related]
32. Metastatic sympathetic paraganglioma in a patient with loss of the SDHC gene.
Rich T; Jackson M; Roman-Gonzalez A; Shah K; Cote GJ; Jimenez C
Fam Cancer; 2015 Dec; 14(4):615-9. PubMed ID: 26162468
[TBL] [Abstract][Full Text] [Related]
33. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
34. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.
Schiavi F; Boedeker CC; Bausch B; Peçzkowska M; Gomez CF; Strassburg T; Pawlu C; Buchta M; Salzmann M; Hoffmann MM; Berlis A; Brink I; Cybulla M; Muresan M; Walter MA; Forrer F; Välimäki M; Kawecki A; Szutkowski Z; Schipper J; Walz MK; Pigny P; Bauters C; Willet-Brozick JE; Baysal BE; Januszewicz A; Eng C; Opocher G; Neumann HP;
JAMA; 2005 Oct; 294(16):2057-63. PubMed ID: 16249420
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients.
Bayley JP; Weiss MM; Grimbergen A; van Brussel BT; Hes FJ; Jansen JC; Verhoef S; Devilee P; Corssmit EP; Vriends AH
Endocr Relat Cancer; 2009 Sep; 16(3):929-37. PubMed ID: 19546167
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
Persu A; Lannoy N; Maiter D; Mendola A; Montigny P; Oriot P; Vinck W; Garin P; Hamoir M; Vikkula M
Horm Metab Res; 2012 May; 44(5):349-53. PubMed ID: 22566194
[TBL] [Abstract][Full Text] [Related]
37. Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes.
Withey SJ; Perrio S; Christodoulou D; Izatt L; Carroll P; Velusamy A; Obholzer R; Lewington V; Jacques AET
Radiographics; 2019; 39(5):1393-1410. PubMed ID: 31498738
[TBL] [Abstract][Full Text] [Related]
38. Germinal defects of SDHx genes in patients with isolated pituitary adenoma.
Mougel G; Lagarde A; Albarel F; Essamet W; Luigi P; Mouly C; Vialon M; Cuny T; Castinetti F; Saveanu A; Brue T; Barlier A; Romanet P
Eur J Endocrinol; 2020 Oct; 183(4):369-379. PubMed ID: 32621582
[TBL] [Abstract][Full Text] [Related]
39. Higher risk of phaeochromocytoma/paraganglioma (Phaeo-Pgl) in SDHD than SDHB carriers: an Australian cohort study.
Hong A; Shanahan M; Schenberg T; Inder W; MacIsaac R; James P; Sachithanandan N
Intern Med J; 2019 Apr; 49(4):529-532. PubMed ID: 30957378
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
Astuti D; Hart-Holden N; Latif F; Lalloo F; Black GC; Lim C; Moran A; Grossman AB; Hodgson SV; Freemont A; Ramsden R; Eng C; Evans DG; Maher ER
Clin Endocrinol (Oxf); 2003 Dec; 59(6):728-33. PubMed ID: 14974914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
